Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,334 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05098197 | A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital) | recruiting | Early Phase 1 | 50 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04430452 | Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma | recruiting | Phase 2 | 21 | Mary Feng, MDOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04204850 |
| Cabozantinib to Treat Recurrent Liver Cancer Post Transplant |
| recruiting |
| Phase 2 |
| 20 |
| University Health Network, TorontoOTHER |
| 1 |
| Dec 3, 2025 |
| clinicaltrials |
| NCT04248569 | DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma | recruiting | Phase 1 | 56 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06172205 | Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC | recruiting | Phase 3 | 262 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06515314 | HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors | recruiting | Phase 1 | 12 | Shanghai Ruiliyuan Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07157969 | ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | recruiting | Phase 2 | 300 | Peking Union Medical College HospitalOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06632717 | Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 24 | National Taiwan University HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07239245 | Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo(ATTACH) | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07243691 | Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma | recruiting | N/A | 33 | Sir Run Run Shaw HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06544629 | Imjudo & Imfinzi PMS | recruiting | — | 246 | AstraZenecaINDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07235410 | Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE | recruiting | — | 300 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT05751343 | Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial | recruiting | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06698250 | Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)(ZENOBIA) | recruiting | Phase 2 | 40 | Anwaar SaeedOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT06198296 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | recruiting | Phase 1 | 21 | Baylor College of MedicineOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT03551951 | Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow | recruiting | — | 320 | University of Missouri-ColumbiaOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT06789757 | The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)((HCC)) | recruiting | Phase 2 | 19 | Inova Health Care ServicesOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05377034 | Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients(STRATUM) | recruiting | Phase 2 | 100 | National Cancer Centre, SingaporeOTHER | 4 | Oct 6, 2025 | clinicaltrials |
| NCT06349317 | Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT | recruiting | Phase 2 | 33 | Yongyi ZengOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06467799 | Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC | recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT07192185 | Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab | recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05971108 | Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC(REVISE-HCC) | recruiting | N/A | 600 | Manchester University NHS Foundation TrustOTHER_GOV | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06644937 | Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence | recruiting | Phase 2 / Phase 3 | 30 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07188311 | Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children | recruiting | N/A | 24 | Sun Yat-sen UniversityOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06658782 | Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer(AMULET) | recruiting | — | 300 | University of OxfordOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07186010 | Immunogenomic Dynamics and Biomarkers in Patients With Hepatocellular Carcinoma Receiving Immunotherapy | recruiting | — | 50 | Asan Medical CenterOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07186621 | Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC | recruiting | Phase 3 | 286 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT04525833 | Liver Disease and Other Systemic Diseases | recruiting | — | 15,000 | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07178093 | Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization | recruiting | N/A | 60 | Taichung Tzu Chi HospitalOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07176962 | A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening | recruiting | — | 1,800 | Yingbin Liu, MD, PhD, FACSOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07170345 | Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion(HCC-MVI-CAD) | recruiting | — | 400 | Chinese Academy of SciencesOTHER_GOV | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06179602 | Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors(A-IMAGIO) | recruiting | — | 1,500 | Leiden University Medical CenterOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06999694 | Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC(Proton-STRIDE) | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07148310 | Hepatocellular Carcinoma Identification Using Delta-HLD(HIDE) | recruiting | — | 200 | Epiliquid Holding, IncINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07154082 | Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma | recruiting | Phase 2 | 27 | Wei ZhangOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06873659 | SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 96 | Qurgen Inc.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06902389 | A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 30 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06541990 | Psychoeducational Intervention for Patients With Hepatocellular Carcinoma(HARMONY) | recruiting | N/A | 50 | Massachusetts General HospitalOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT06374485 | Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment | recruiting | Phase 1 | 18 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Aug 26, 2025 | clinicaltrials |
| NCT07141056 | The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study(SOLACE) | recruiting | — | 700 | Guilin Medical University, ChinaOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT07142213 | Effect and Mechanism of ALPPS Operation on Liver Regeneration | recruiting | — | 50 | Haitao Zhao, MDOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06508307 | A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors | recruiting | Phase 1 | 21 | GONGCHU Biotechnology Co., LtdOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT06777485 | China Liver Cancer Clinical Registry Cohort Database (HEAL) | recruiting | — | 10,000 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 20, 2025 | clinicaltrials |
| NCT06084299 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer | recruiting | Phase 1 | 16 | Zhiyong HuangOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07100392 | Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab(LEAF-02) | recruiting | Phase 2 | 141 | Fudan UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Dec 11, 2025source: clinicaltrials